Context

Modafinil vs alternatives

A factual side-by-side view of five compounds people encounter in discussions of alertness. This is a comparison of mechanisms, durations and evidence quality, not a ranking, and not a recommendation.

Modafinil

Wakefulness-promoting agent

Primary mechanism: Weak dopamine reuptake inhibition, with orexin and histamine involvement
Typical duration: Long, commonly described as covering a working day
Evidence base: Trials in narcolepsy, sleep apnea and shift work sleep disorder
Notable risks: Rash, psychiatric effects, interactions through liver enzymes

Armodafinil

Wakefulness-promoting agent

Primary mechanism: The same pathways as modafinil, using the R enantiomer alone
Typical duration: Long, with a plasma profile that differs from racemic modafinil
Evidence base: Trials in the same sleepiness indications
Notable risks: Broadly comparable adverse effect profile to modafinil

Adderall

Amphetamine salt stimulant

Primary mechanism: Dopamine and norepinephrine release by transporter reversal, plus reuptake blockade
Typical duration: About 4 to 6 hours for immediate release, about 12 hours for extended release
Evidence base: Registration trials in ADHD and narcolepsy
Notable risks: Boxed warning for abuse and addiction, cardiovascular strain, appetite and sleep disruption, withdrawal on stopping

Caffeine

Widely available stimulant

Primary mechanism: Adenosine receptor antagonism
Typical duration: Short to moderate, several hours
Evidence base: Extensive literature on alertness and vigilance
Notable risks: Tolerance, withdrawal headache, disrupted sleep, anxiety at high doses

L-Theanine

Amino acid, dietary supplement

Primary mechanism: Proposed modulation of glutamate and GABA signalling
Typical duration: Short, studied in single dose designs
Evidence base: Small trials, often combined with caffeine, with mixed results
Notable risks: Generally reported as well tolerated, with limited long term data

Reading the comparison

Each point below explains why the rows above differ, and where the comparison breaks down.

Mechanism is not interchangeable

Modafinil and armodafinil act on monoamine and orexin systems; Adderall releases dopamine and norepinephrine directly and far more strongly; caffeine works through adenosine receptors; L-theanine is studied for effects on inhibitory signalling. These are different targets, so results from one compound do not transfer to another.

Amphetamines sit in a different risk class

Adderall is a Schedule II amphetamine with documented dependence potential, cardiovascular effects and a withdrawal pattern on discontinuation. Wakefulness-promoting agents are described in the literature as having a lower reinforcement profile, but that difference is one of degree rather than an absence of risk.

Duration changes the trade-off

Longer-acting compounds can interfere with subsequent sleep if taken late. Shorter-acting ones require repeat dosing. Duration figures in the literature are averages and vary with metabolism and formulation.

Study populations differ

Wakefulness agents have mostly been examined in sleep-deprived or clinically diagnosed groups, while caffeine and L-theanine are more often studied in rested volunteers. Baseline state shapes what any trial can detect, so results do not transfer between these settings.

Evidence quality differs sharply

Wakefulness-promoting agents have been tested in registration trials for defined indications. Supplement literature is typically smaller, shorter and more heterogeneous. Comparing them on a single scale would be misleading.